First Trust Advisors’s ADMA Biologics ADMA Stock Holding History

First Trust Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.3M	Buy	7,798,351 +7,438,134	+2,065%	+$67.8M	0.04%	515
2026 Q1	$3.25M	Buy	360,217 +335,564	+1,361%	+$5.3M	﹤0.01%	1690
2025 Q4	$450K	Sell	24,653 -213,904	-90%	-$3.61M	﹤0.01%	2359
2025 Q3	$3.5M	Sell	238,557 -73,631	-24%	-$1.26M	﹤0.01%	1560
2025 Q2	$5.68M	Sell	312,188 -7,160	-2%	-$146K	﹤0.01%	1301
2025 Q1	$6.34M	Sell	319,348 -13,961	-4%	-$241K	0.01%	1209
2024 Q4	$5.72M	Sell	333,309 -227,919	-41%	-$4.29M	0.01%	1294
2024 Q3	$11.2M	Sell	561,228 -162,354	-22%	-$2.52M	0.01%	1006
2024 Q2	$8.09M	Buy	+723,582	New	+$6.07M	0.01%	1088

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors's ADMA Position: Q2 2026 in Review

First Trust Advisors increased its ADMA Biologics (ADMA) stake by 2,065% in Q2 2026, buying an estimated $67.8M and bringing the position to 7,798,351 shares worth $65.3M. The position accounts for 0.04% of the portfolio, ranked #515.

First Trust Advisors first reported a position in ADMA in Q2 2024 and has held it in 9 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

First Trust Advisors held 7,798,351 shares of ADMA Biologics worth $65.3M as of Q2 2026.
First Trust Advisors bought 7,438,134 ADMA Biologics shares in Q2 2026, an estimated $67.8M.
ADMA Biologics made up 0.04% of First Trust Advisors's portfolio in Q2 2026, its #515 holding.
First Trust Advisors first reported a position in ADMA Biologics in Q2 2024 and has held it in 9 quarters since.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.